India · Delayed Price · Currency is INR Sudeep Pharma Statistics
Total Valuation
Sudeep Pharma has a market cap or net worth of INR 136.40 billion. The enterprise value is 137.29 billion.
| Market Cap | 136.40B |
| Enterprise Value | 137.29B |
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Jul 23, 2026 |
Share Statistics
Sudeep Pharma has 112.95 million shares outstanding. The number of shares has increased by 4.52% in one year.
| Current Share Class | 112.95M |
| Shares Outstanding | 112.95M |
| Shares Change (YoY) | +4.52% |
| Shares Change (QoQ) | -0.76% |
| Owned by Insiders (%) | 37.13% |
| Owned by Institutions (%) | 20.33% |
| Float | 25.44M |
Valuation Ratios
The trailing PE ratio is 72.76 and the forward PE ratio is 64.72. Sudeep Pharma's PEG ratio is 4.01.
| PE Ratio | 72.76 |
| Forward PE | 64.72 |
| PS Ratio | 19.22 |
| PB Ratio | 14.02 |
| P/TBV Ratio | 15.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 143.09 |
| PEG Ratio | 4.01 |
Enterprise Valuation
| EV / Earnings | 72.90 |
| EV / Sales | 19.35 |
| EV / EBITDA | 54.78 |
| EV / EBIT | 58.78 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.91, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.91 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | n/a |
| Interest Coverage | 29.25 |
Financial Efficiency
Return on equity (ROE) is 22.04% and return on invested capital (ROIC) is 17.81%.
| Return on Equity (ROE) | 22.04% |
| Return on Assets (ROA) | 12.60% |
| Return on Invested Capital (ROIC) | 17.81% |
| Return on Capital Employed (ROCE) | 21.63% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 13.52M |
| Profits Per Employee | 3.59M |
| Employee Count | 525 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.11 |
Taxes
In the past 12 months, Sudeep Pharma has paid 611.59 million in taxes.
| Income Tax | 611.59M |
| Effective Tax Rate | 24.48% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1,141.25 |
| 200-Day Moving Average | 849.42 |
| Relative Strength Index (RSI) | 62.31 |
| Average Volume (20 Days) | 268,099 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sudeep Pharma had revenue of INR 7.10 billion and earned 1.88 billion in profits. Earnings per share was 16.60.
| Revenue | 7.10B |
| Gross Profit | 4.56B |
| Operating Income | 2.34B |
| Pretax Income | 2.50B |
| Net Income | 1.88B |
| EBITDA | 2.50B |
| EBIT | 2.34B |
| Earnings Per Share (EPS) | 16.60 |
Balance Sheet
The company has 1.15 billion in cash and 1.89 billion in debt, with a net cash position of -742.87 million or -6.58 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 1.89B |
| Net Cash | -742.87M |
| Net Cash Per Share | -6.58 |
| Equity (Book Value) | 9.73B |
| Book Value Per Share | 85.40 |
| Working Capital | 4.74B |
Cash Flow
In the last 12 months, operating cash flow was 953.25 million and capital expenditures -1.34 billion, giving a free cash flow of -388.76 million.
| Operating Cash Flow | 953.25M |
| Capital Expenditures | -1.34B |
| Depreciation & Amortization | 161.02M |
| Net Borrowing | 440.36M |
| Free Cash Flow | -388.76M |
| FCF Per Share | -3.44 |
Margins
Gross margin is 64.24%, with operating and profit margins of 32.92% and 26.54%.
| Gross Margin | 64.24% |
| Operating Margin | 32.92% |
| Pretax Margin | 35.20% |
| Profit Margin | 26.54% |
| EBITDA Margin | 35.19% |
| EBIT Margin | 32.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.12%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 0.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.99% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.52% |
| Shareholder Yield | -4.40% |
| Earnings Yield | 1.37% |
| FCF Yield | -0.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Sudeep Pharma is 1,021.50, which is -15.41% lower than the current price. The consensus rating is "Sell".
| Price Target | 1,021.50 |
| Price Target Difference | -15.41% |
| Analyst Consensus | Sell |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 31.10% |
| EPS Growth Forecast (3Y) | 16.01% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |